UK diversity-hero
The UK’s inclusion and diversity plan will ask “researchers to consider [aspects] beyond participant’s race and ethnicity.”
UK Health Research Authority

About the author

vibha sharma headshot

Vibha Sharma

Senior Writer

Vibha Sharma is a senior writer covering pharmaceutical and medtech regulatory developments across the globe. She plays a key role in tracking and writing about news of important regulatory issues affecting the sectors and explaining their implications for industry. Her fields of interest include the EU regulations on clinical trials, pharmacovigilance and pediatrics, on which she has written several exclusive articles from various industry conferences. She has also commissioned pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.

Related resources

A digital representation of the future of healthcare, showcasing the integration of technology and medicine.
JUN 01, 2023
Whitepaper
研究開発支援サービス

The Need for Better Diversity Data in Clinical Trial Benchmarking and Feasibility

Just as marginalized patients face barriers to clinical trial participation, study sponsors face challenges in obtaining clinical trial diversity data.

A diverse group of people looking up.
NOV 15, 2023
Article
研究開発支援サービス

3 Ways Clinical Trial Diversity Can Put Sponsors On Top

Since the FDA’s draft guidance in 2022, the industry has redoubled its efforts to incorporate diversity at pivotal points in the clinical trial process.

Hand on digital globe exploring the vast data Sitetrove provides globally.
DEC 12, 2023
Infographic
研究開発支援サービス

Make Diverse Trial Recruitment & Enrollment a Priority ― and a Success

Clinical trial sponsors can successfully recruit diverse populations by leveraging the right intelligence to support optimal investigator & site selection. Sitetrove enables sponsors to understand the landscape of clinically relevant and demographically diverse patient populations for US investigators. Patient age, race and gender demographics, can be viewed at the state, city, investigator, and primary organization
levels.